Pfizer presents positive late-stage data for new hemophilia drug
The company is assessing its market registration timeline before submitting its candidate for hemophilia A and B treatment.
by marketwire, translated by daniel pedersen
US-based Pfizer presented on Tuesday positive results from a phase III clinical study of drug candidate marstacimab for the preventive treatment of hemophilia A and B.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
FDA extends review of BioMarin's hemophilia A gene therapy
For subscribers
